Cargando…
厄洛替尼100 mg/天治疗化疗后进展的晚期肺腺癌的临床研究
BACKGROUND AND OBJECTIVE: Erlotinib is a epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). The standard dose is 150 mg/d. But some patients have to reduce the dose or stop treatment due to its side effects. The aim of this study is to evaluate the efficacy and safety of erlotini...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999887/ https://www.ncbi.nlm.nih.gov/pubmed/21645458 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.06.09 |